Tysabri Europäische Union - Deutsch - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalizumab - multiple sklerose - selektive immunsuppressiva - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 und 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Zinbryta Europäische Union - Deutsch - EMA (European Medicines Agency)

zinbryta

biogen idec ltd - daclizumab - multiple sklerose - immunsuppressiva - zinbryta ist bei erwachsenen patienten zur behandlung von schubförmig verlaufenden formen der multiplen sklerose (rms) indiziert..

Spinraza Europäische Union - Deutsch - EMA (European Medicines Agency)

spinraza

biogen netherlands b.v. - nusinersen-natrium - muskelatrophie, spinal - andere medikamente des nervensystems - spinraza ist indiziert zur behandlung der 5q spinalen muskelatrophie.

Vumerity Europäische Union - Deutsch - EMA (European Medicines Agency)

vumerity

biogen netherlands b.v. - diroximel fumarate (biib098) - multiple sklerose, schubförmig-remittierender - immunsuppressiva - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).